MRM Health Completes Patient Recruitment in Ulcerative Colitis Study, Secures Financing and Provides Outlook for 2023
Summary
MRM Healtha clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics based on its proprietary and unique CORAL\xae platform technology - today provided a business update on its different ongoing therapeutic programs and an outlook for 2023.- Top-line data from Phase 2a trial with MH002 in Ulcerative Colitis in Q3 2023 and mechanistic readouts in Q4 2023 - Initial data from open label Phase 2 trial with MH002 in Acute Pouchitis in Q4 2023 - Preclinical proof-of-concept in Type 2 Diabetes program partnered with IFF - Completion of in vivo disease model studies in Parkinsons Disease programIn 2022, we delivered not only on key milestones regarding the progress of our clinical programs, but also on key preclinical targets and we obtained additional dilutive and non-dilutive financing to continue our ambitious growth plans, said Sam Possemiers, Chief Executive Officer of MRM Health. Our effective progress provided confidence to SFPIM to join MRM Health and to partner with our existing investors to close a follow-on financing to continue on our path to success.Clinical Development with MH002 in Ulcerative Colitis and acute PouchitisMRM Healths MH002-UC-201 study is a multi-center, double-blind, randomized, placebo-controlled trial with clinical sites in Belgium, Poland and Czech Republic, designed to evaluate safety, mechanistic effects, and initial efficacy of MH002 on disease activity. Developed through MRM Healths proprietary CORAL\xae Technology, MH002 consists of 6 well-characterized commensal strains, selected and optimized to tackle key disease-driving mechanisms with enhanced potency, resiliency, and engraftment. MH002 is produced using MRM Healths breakthrough scalable and standardized cGMP manufacturing platform, allowing the manufacturing of complete consortia as a single drug substance, expected to provide both key regulatory and patient compliance advantages.In addition, MH002 is currently also being investigated in an ongoing multi-center, open label Phase 2 study enrolling patients with Acute Pouchitis, a rare disease with high unmet medical need.MRM Health has an ongoing corporate partnership with IFF since 2020, aiming to tackle a range of metabolic diseases. Based on recent findings on specific microbiome signatures in PD, obtained from extensive in-house PD patient cohort analysis, and in vivo disease model data showing the capacity of specific bacterial strains to impact the target disease mechanisms, MRM Health was recently awarded a 2M EUR subsidy grant from the Flemish subsidy agency VLAIO.